Start an SGLT-2 Inhibitor Now
For your patient with stage 4 CKD and HbA1c 6.0% (prediabetes), you should initiate an SGLT-2 inhibitor immediately to slow kidney disease progression and reduce cardiovascular mortality, regardless of diabetes status. 1
Why SGLT-2 Inhibitors Are the Clear Choice
The 2024 BMJ guideline provides a strong recommendation for SGLT-2 inhibitors in adults at high to very high risk of CKD progression (which includes stage 4 CKD), and this recommendation explicitly applies to all adults with CKD, irrespective of type 2 diabetes status 1. Your patient with stage 4 disease falls into the high-risk category even without overt diabetes.
The evidence is compelling:
- Moderate to high certainty evidence shows SGLT-2 inhibitors decrease all-cause mortality, cardiovascular mortality, hospitalization for heart failure, kidney failure, non-fatal MI, and non-fatal stroke 1
- The 2026 AHA/ACC/ADA/ASN guideline reinforces this with a Class 1, Level A recommendation for SGLT-2 inhibitors in CKD with eGFR ≥20 mL/min/1.73 m² 2
Practical Implementation
Which SGLT-2 Inhibitor to Choose
- Dapagliflozin or empagliflozin are both appropriate
- Both can be initiated down to eGFR ≥20 mL/min/1.73 m² 2
- Continue therapy even as eGFR declines below initiation threshold
Key Monitoring Points
- Check eGFR and electrolytes 2-4 weeks after initiation
- Expect an initial eGFR dip of 5-10 mL/min/1.73 m² (this is hemodynamic and acceptable—do not discontinue)
- Monitor for volume depletion, especially if patient is on diuretics
- Screen for genital mycotic infections (more common in women)
Why Not Wait for Diabetes to Develop
The prediabetes state (HbA1c 6.0%) is already independently associated with kidney impairment and accelerated eGFR decline 3. Each 1% increase in HbA1c correlates with a 4.6 mL/min/1.73 m² decrease in eGFR 3. Waiting for frank diabetes means missing a critical window for renal protection.
The landmark trials supporting SGLT-2 inhibitors enrolled participants with and without diabetes, demonstrating benefit across the spectrum 1. The mechanisms of renal protection extend beyond glucose lowering—they include hemodynamic effects, reduced intraglomerular pressure, and anti-inflammatory properties.
Common Pitfalls to Avoid
Don't discontinue during acute illness: Temporarily hold during severe dehydration or acute kidney injury, but reinitiate once resolved 4. Permanent discontinuation is a major implementation gap.
Don't wait for "better" glycemic control: The renal and cardiovascular benefits occur independently of baseline glucose levels 1
Don't be deterred by stage 4 CKD: Current evidence supports a monitoring-based approach in CKD G4, with initiation appropriate if eGFR ≥20 mL/min/1.73 m² 4
Future Considerations
If albuminuria is present (check urine albumin-to-creatinine ratio if not already done), consider adding:
- RAS inhibitor (ACE inhibitor or ARB) if not already on one and blood pressure tolerates
- Finerenone (nonsteroidal MRA) for persistent albuminuria despite RAS inhibition 5, 6
GLP-1 receptor agonists could be considered if additional cardiovascular risk reduction or weight management is needed, but SGLT-2 inhibitors should be the first-line renal protective therapy 7, 8.
The Bottom Line
Your patient's stage 4 CKD with prediabetes represents high absolute risk for kidney failure and cardiovascular events. The evidence unequivocally supports SGLT-2 inhibitor initiation now, not waiting for diabetes diagnosis. The diet and exercise regimen should continue alongside pharmacotherapy—these are complementary, not alternative strategies 9.